Melatonin Use in Pregnancy Remains an Evidence Gap
Sleep disturbance is common during pregnancy, and the burden rises as gestation advances. Insomnia is particularly frequent in the third trimester, when physical discomfort, nocturnal awakenings, reflux, fetal movement, and anxiety can converge into persistent sleep loss. In clinical practice, that problem is not trivial: chronic poor sleep can strain daytime function and may increase vulnerability to perinatal depression and anxiety.
Melatonin is often the first supplement patients reach for because it is familiar, inexpensive, and sold over the counter. The appeal is understandable. The hormone has a clear physiologic role in sleep-wake regulation, and it is also present in reproductive biology in ways that go far beyond drowsiness. The clinical question is narrower and more difficult: whether supplemental melatonin is safe and effective when used as a sleep aid during pregnancy.
Placental Biology Explains the Interest, Not the Answer
Melatonin is synthesized primarily by the pineal gland under control of the light-dark cycle, but the placenta also produces it. Maternal levels follow a circadian pattern and rise as pregnancy progresses, with nighttime concentrations increasing substantially after about 24 weeks of gestation. Because melatonin crosses the placenta and reaches the fetal circulation, it can interact with receptors involved in circadian regulation and fetal development.
Its biological profile has made it an attractive candidate for study in obstetric medicine. Melatonin has antioxidant, anti-inflammatory, and neuroprotective properties, and oxidative stress has been implicated in complications such as preeclampsia, fetal growth restriction, and preterm birth. Experimental work suggests melatonin may protect placental cells from oxidative injury and modulate inflammatory pathways. In theory, those effects could support placental function in pregnancies complicated by dysfunction.
A theory, however, is not a treatment recommendation.
Human pregnancy is exposed to a much more complicated reality than cell culture or animal models. Supplemental products can generate blood concentrations far above endogenous physiologic levels, and prenatal exposure depends on dose, formulation, and maternal metabolism. The fetal implications of those higher concentrations remain uncertain.
Human Studies Have Not Found Major Safety Signals, But the Data Are Thin
Existing human evidence does not provide a strong safety alarm, yet it also does not provide enough reassurance to endorse routine use. The available studies have mainly examined melatonin as a potential therapy for obstetric complications such as preeclampsia, hyperglycemia, and fetal growth restriction rather than as a hypnotic for insomnia. Small clinical studies have not identified major safety concerns, even when relatively high doses were used. Still, those studies were not designed or powered to detect uncommon outcomes such as congenital malformations or rare adverse pregnancy events.
A scoping review of melatonin use during pregnancy and lactation found only a limited number of human studies. The overall clinical signal was not one of obvious harm, but the evidence base was too small to establish either safety or efficacy for sleep disturbance during pregnancy. That distinction matters in counseling. “No major signal” is not the same as “proven safe,” especially in a population where even small fetal risks carry outsized consequences.
Animal data have added to the uncertainty rather than settling it. Some preclinical studies have raised concerns about fetal growth, offspring development, and circadian regulation, while others suggest possible neuroprotective effects. None of those findings translate cleanly into clinical guidance for pregnant patients, but they reinforce the need to avoid false confidence in a supplement simply because it is naturally occurring.
Over-the-Counter Formulations Complicate Counseling at the Bedside
Commercial melatonin products are not regulated like prescription medications. In the United States, melatonin is marketed as a dietary supplement, so the FDA does not evaluate these products for safety and efficacy before they reach consumers in the same way it does for approved drugs. Actual content and quality can vary between formulations, and prenatal exposure therefore may not match what patients think they are taking.
For the pregnant patient asking whether a low-dose tablet is “just a hormone,” the answer is more complicated. Endogenous melatonin is part of normal physiology, but supplemental melatonin can produce higher circulating concentrations than the body would ordinarily generate. In pregnancy, where placental transfer is expected and fetal circadian systems are developing, that difference is clinically relevant.
This is why broad reassurance is difficult. The available data have not identified a major teratogenic signal, but the evidence remains insufficient to establish routine use for insomnia in pregnancy. Clinicians should not equate OTC availability with established prenatal safety.
CBT-I Should Anchor Treatment for Persistent Insomnia
When sleep disturbance becomes persistent or begins to impair daytime function, treatment is still warranted. The most evidence-based nonpharmacologic option is cognitive behavioral therapy for insomnia (CBT-I). In pregnancy, that approach is especially valuable because it avoids fetal drug exposure while addressing the behavioral and cognitive drivers of chronic insomnia.
Medication decisions should be individualized. Severity of the sleep complaint, the trimester, comorbid psychiatric symptoms, prior response to nonpharmacologic treatment, and the patient’s preferences all belong in the discussion. If pharmacotherapy is being considered, the limited pregnancy safety data for melatonin should be part of the conversation, not an afterthought.
The practical bedside message is straightforward: sleep disruption during pregnancy deserves attention, but the current evidence does not support melatonin as an established treatment. Clinicians should discuss the limitations of the data directly with women who are pregnant or planning conception, and they should avoid presenting a supplement with uncertain prenatal exposure as though it were benign by default.
The Remaining Question Is Clinical, Not Theoretical
More research is needed to determine whether supplemental melatonin can safely and effectively treat insomnia in pregnancy. For now, the evidence supports caution rather than routine use. Human studies have not identified major safety signals, but they are too limited to rule out uncommon harms or to establish efficacy for sleep.
Until stronger data emerge, the most defensible approach is to favor CBT-I and other evidence-based strategies, reserve medication for carefully selected cases, and keep counseling grounded in what is known rather than what is assumed. Pregnancy changes the threshold for certainty, and melatonin has not yet crossed it.